Global Health News Brief: Restructuring and Strategic Moves
A summary of recent health-related developments, covering topics such as Surgery Partners rejecting Bain Capital's offer, U.S. pharmaceuticals focusing on China for drug deals, Purdue Pharma securing support for a $7.4 billion opioid settlement, and Kraft Heinz's commitment to eliminating artificial colors by 2027.
In recent health sector developments, Surgery Partners has announced its rejection of Bain Capital's take-private proposal due to disagreements over terms, leading to a 13% drop in share value.
Meanwhile, U.S. pharmaceutical companies are increasingly turning to Chinese companies for licensing deals, aiming to transform them into lucrative treatments, with 14 deals amounting to $18.3 billion signed so far this year.
Additionally, Purdue Pharma's proposed $7.4 billion settlement, addressing numerous opioid lawsuits, has garnered substantial support from state attorneys general, potentially facilitating court approval for bankruptcy reorganization.
(With inputs from agencies.)
Advertisement
ALSO READ
Europe Faces Rising Threat from New Opioids and Designer Drugs
Potential Vision Risks Associated with Novo's Weight-Loss Drugs
Punjab Anti-Gangster Task Force Cracks Down on Fugitives, Recovers Weapons and Drugs
Punjab's Resolute War on Drugs: A People's Movement Gaining Traction
Rapid Review Revolution: FDA's New Fast-Track Initiative for Drugs
Google News